OptimizeRx Corporation revised earnings guidance for the year 2023. Preliminary revenue for 2023 is expected to exceed the Company?s previously announced guidance range of $68-$70 million. The stronger-than-expected top-line performance was driven by end of year success with DAAP (Dynamic Audience Activation Platform), as the Company closed the year with 24 deals.

This is expected to result in a sequential improvement to the Company?s KPIs.